Items where authors include "Sundar, S."
Article
Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370
Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642
Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723
Lakhiani, A., Cummins, C. orcid.org/0000-0001-5464-1944, Kumar, S. et al. (16 more authors) (2023) Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study. Cancers, 16 (1). 75. ISSN 2072-6694
Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587
Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736
Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045
Crabb, S.J. orcid.org/0000-0003-3521-9064, Hussain, S. orcid.org/0000-0003-1552-511X, Soulis, E. orcid.org/0000-0001-9022-9295 et al. (18 more authors) (2023) A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41 (1). pp. 54-64. ISSN 0732-183X
Glasbey, J.C., Abbott, T.E.F., Ademuyiwa, A. et al. (4500 more authors) (2022) Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries. The Lancet, 400 (10363). pp. 1607-1617. ISSN 0140-6736
Cummins, C., Kumar, S., Long, J. et al. (14 more authors) (2022) Investigating the impact of ultra-radical surgery on survival in advanced ovarian cancer using population-based data in a multicentre UK study. Cancers, 14 (18). 4362. ISSN 2072-6694
Sundar, S., Cummins, C., Kumar, S. et al. (17 more authors) (2022) Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. BJOG: An International Journal of Obstetrics & Gynaecology, 129 (7). pp. 1122-1132. ISSN 1470-0328
Voss, M.A., Gordon, N., Maloney, S. et al. (8 more authors) (2011) Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. British Journal of Cancer, 104 (10). pp. 1611-1618. ISSN 0007-0920